Stock 2696 SHANGHAI HENLIUS BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Relative Strength Chart Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Delayed Hong Kong S.E.
Other stock markets
 11:53:25 2024-05-12 pm EDT 		5-day change 1st Jan Change
17.2 HKD 0.00% Intraday chart for Shanghai Henlius Biotech, Inc. +3.61% +23.74%
May. 06 Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy MT
May. 06 Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration CI

End-of-day quotes

Compared values

Sector Change 5d. change 1st Jan change 1-year change 5-years change Capi. ST MT LT
SHANGHAI HENLIUS BIOTECH, INC.
Biopharmaceuticals
0.00%+3.61%+23.74%+27.03% - 1.2B
Bullish
Bullish
Bullish
  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. Charts Shanghai Henlius Biotech, Inc.
  5. Relative Strength Chart
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW